How much revenue does Lupin make?

Lupin reported 221.92 billion INR in revenue for fiscal year 2025, up 12.9% from 196.56 billion INR in fiscal year 2024. In Q1 2026 revenue was 61.64 billion INR.

What is Lupin's largest business segment?

Pharmaceuticals, with 226.04 billion INR or 100% of segment revenue in fiscal year 2025. Next: Others (under 1%).

Where does Lupin make most of its revenue?

India: 37% of revenue by region in fiscal year 2025, followed by USA (34%).

What companies are similar to Lupin?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Cipla Limited (CIPLA.NS), Mankind Pharma Limited (MANKIND.NS), Aurobindo Pharma Limited (AUROPHARMA.NS), Glenmark Pharmaceuticals Limited (GLENMARK.NS).

Lupin Limited (LUPIN.NS) Stock

About Lupin Limited

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It produces, develops, and markets various branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company also offers products in the therapeutic a...

At a glance

Lupin reported revenue of 221.92 billion INR for fiscal year 2025, up 12.9% from fiscal year 2024, and net income of 32.82 billion INR. In Q1 2026 (the quarter ended June 30, 2025) revenue was 61.64 billion INR, up 11.8% from a year before. Its largest business segment, Pharmaceuticals, brought in 100% of segment revenue in fiscal year 2025; India was the largest region with 37%.

Figures from company filings; latest fiscal year ended March 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.